Reduced Weight Regain: CCT-217 shows promise in preventing weight regain commonly observed after discontinuing incretin ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the ...

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...

The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Venture capital firms incubate, grow and finance dozens of drug companies each year. Follow the money they channel into the ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its ...